Zuzanna Zarzycka
Zuzanna Zarzycka has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Donata Pokorska
The Voivodal Specialistic Hospital, Olsztyn, Poland
8 shared publications - Ingrid Samberger
7th Navy Hospital, Gdańsk, Poland
8 shared publications - Judyta Bordakiewicz
7th Navy Hospital, Gdańsk, Poland
8 shared publications - Julia Maria Kuczkowska
7th Navy Hospital, Gdańsk, Poland
8 shared publications - Julia Świechowska
Uniwersyteckie Centrum Kliniczne w Gdańsku, Gdańsk, Poland
8 shared publications - Magdalena Wiciak
Uniwersyteckie Centrum Kliniczne w Gdańsku, Gdańsk, Poland
8 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Institute of Rural Health in Environmental Medicine
- Vol. 29 (2) , 55-61
Impact of climate change on the epidemiology of tick-borne encephalitis in Europe – a narrative review
Introduction and objective: Tick-borne encephalitis (TBE) is an important viral infection caused by Flavivirus, primarily transmitted by Ixodes ricinus ticks. Its incidence and geographic range are increasing across Europe. The aim of the review is to assess currently available evidence on...
- 22 September 2026
- Published by Institute of Rural Health in Environmental Medicine
- Vol. 29 (2) , 55-61
Open AccessImpact of climate change on the epidemiology of tick-borne encephalitis in Europe – a narrative review
Introduction and objective: Tick-borne encephalitis (TBE) is an important viral infection caused by Flavivirus, primarily transmitted by Ixodes ricinus ticks. Its incidence and geographic range are increasing across Europe. The aim of the review is to assess currently available evidence on...
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
BURNOUT AND MORAL INJURY AMONG RESIDENTS AND EARLY-CAREER PHYSICIANS: AN INTERNATIONAL REVIEW OF OBSERVATIONAL EVIDENCE
Background. Burnout among healthcare workers is now recognised as a public-health concern in its own right, with residents and early-career physicians disproportionately affected. The construct of moral injury — distress arising when clinicians cannot act in accordance with their professional values because of system-level constraints — has been proposed as a complement to the classical burnout framework. Aim. To synthesise contemporary observational evidence on the epidemiology of burnout, its principal risk factors, and the role of moral injury among residents and early-career physicians, with particular attention to the Polish context. Methods. A literature review of observational studies published between 2009 and 2025 was conducted in PubMed, Scopus, and Web of Science, following the STROBE statement for reporting. Because of methodological heterogeneity, no quantitative meta-analysis was attempted; findings were integrated through qualitative narrative synthesis. Results. Burnout prevalence in this population ranged from approximately 30% to over 60%, depending on geography, specialty, and measurement instrument [11,12]. Dominant risk factors were organisational: excessive workload, administrative load, restricted professional autonomy, and impaired work–life balance. Personal attributes rarely operated as independent predictors but appeared to modify risk. Moral injury emerged as a meaningful complement to burnout, capturing the value-conflict dimension that burnout scales tend to miss [8,9]. Conclusions. Burnout and moral injury together pose a serious challenge to healthcare systems. Prevention strategies that focus exclusively on individual resilience are unlikely to succeed; the evidence points instead to structural and organisational reform [31].
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessBURNOUT AND MORAL INJURY AMONG RESIDENTS AND EARLY-CAREER PHYSICIANS: AN INTERNATIONAL REVIEW OF OBSERVATIONAL EVIDENCE
Background. Burnout among healthcare workers is now recognised as a public-health concern in its own right, with residents and early-career physicians disproportionately affected. The construct of moral injury — distress arising when clinicians cannot act in accordance with their professional values because of system-level constraints — has been proposed as a complement to the classical burnout framework. Aim. To synthesise contemporary observational evidence on the epidemiology of burnout, its principal risk factors, and the role of moral injury among residents and early-career physicians, with particular attention to the Polish context. Methods. A literature review of observational studies published between 2009 and 2025 was conducted in PubMed, Scopus, and Web of Science, following the STROBE statement for reporting. Because of methodological heterogeneity, no quantitative meta-analysis was attempted; findings were integrated through qualitative narrative synthesis. Results. Burnout prevalence in this population ranged from approximately 30% to over 60%, depending on geography, specialty, and measurement instrument [11,12]. Dominant risk factors were organisational: excessive workload, administrative load, restricted professional autonomy, and impaired work–life balance. Personal attributes rarely operated as independent predictors but appeared to modify risk. Moral injury emerged as a meaningful complement to burnout, capturing the value-conflict dimension that burnout scales tend to miss [8,9]. Conclusions. Burnout and moral injury together pose a serious challenge to healthcare systems. Prevention strategies that focus exclusively on individual resilience are unlikely to succeed; the evidence points instead to structural and organisational reform [31].
- Open Access
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
LIVING ALONGSIDE DISABILITY: THE MENTAL HEALTH RISK IN SIBLING RELATIONSHIPS. A REVIEW
This review aims to examine the psychological, psychiatric, and social outcomes among siblings of pediatric patients affected by disabilities, encompassing mental, neurodevelopmental, genetic, oncological, and somatic disorders. Despite extensive research on patients, the experiences of siblings remain underexplored, although existing evidence suggests that they represent a vulnerable group at increased risk for mental health issues and decreased quality of life. A literature review was conducted focusing on studies published within the last five years to ensure accuracy and novelty. Findings indicate that siblings of affected youth frequently endure emotional distress, including anxiety, guilt, and helplessness, in addition to disturbances in family dynamics and reduced parental attention. Increased caregiving obligations often result in exhaustion, social limitations, and a perceived deprivation of childhood. Across conditions, sibling psychopathology emerged as a key mediator of reduced quality of life. While some siblings demonstrate adaptive mechanisms and develop prosocial traits, others remain at risk of persistent psychological difficulties. Severity and type of illness influence outcomes, with particularly high levels of trauma- related symptoms and, in some instances, increased physical morbidity among siblings of children with cancer, whereas genetic conditions are associated with high rates of sleep disturbances. Siblings of individuals with disabilities are significantly affected across multiple domains of functioning. The burden is multifactorial and influenced by illness severity, family context, and individual characteristics. These findings highlight the need for systematic recognition of siblings’ needs and the implementation of targeted psychosocial interventions as part of comprehensive, family-centered care.
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessLIVING ALONGSIDE DISABILITY: THE MENTAL HEALTH RISK IN SIBLING RELATIONSHIPS. A REVIEW
This review aims to examine the psychological, psychiatric, and social outcomes among siblings of pediatric patients affected by disabilities, encompassing mental, neurodevelopmental, genetic, oncological, and somatic disorders. Despite extensive research on patients, the experiences of siblings remain underexplored, although existing evidence suggests that they represent a vulnerable group at increased risk for mental health issues and decreased quality of life. A literature review was conducted focusing on studies published within the last five years to ensure accuracy and novelty. Findings indicate that siblings of affected youth frequently endure emotional distress, including anxiety, guilt, and helplessness, in addition to disturbances in family dynamics and reduced parental attention. Increased caregiving obligations often result in exhaustion, social limitations, and a perceived deprivation of childhood. Across conditions, sibling psychopathology emerged as a key mediator of reduced quality of life. While some siblings demonstrate adaptive mechanisms and develop prosocial traits, others remain at risk of persistent psychological difficulties. Severity and type of illness influence outcomes, with particularly high levels of trauma- related symptoms and, in some instances, increased physical morbidity among siblings of children with cancer, whereas genetic conditions are associated with high rates of sleep disturbances. Siblings of individuals with disabilities are significantly affected across multiple domains of functioning. The burden is multifactorial and influenced by illness severity, family context, and individual characteristics. These findings highlight the need for systematic recognition of siblings’ needs and the implementation of targeted psychosocial interventions as part of comprehensive, family-centered care.
- Open Access
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
NEUROINFLAMMATION AFTER MUSCULOSKELETAL TRAUMA - MISSING LINK BETWEEN ORTHOPEDIC INJURY AND CHRONIC PAIN?
Musculoskeletal injuries, such as fractures and whiplash, affect around 9 million people annually and are a major cause of disability. In many cases, pain persists despite tissue healing, which is not fully explained by traditional models. Increasing evidence suggests that neuroinflammation - the activation of the innate immune system in the peripheral and central nervous systems - may underlie chronic pain. It involves glial cell activation and the release of proinflammatory mediators, leading to central sensitization and maladaptive synaptic plasticity. To evaluate neuroinflammation as a potential “missing link” between orthopedic injury and chronic pain, and to identify therapeutic targets. A search of PubMed, Web of Science and Google Scholar was conducted. Included were randomized controlled trials, systematic review and meta-analyses of ankle sprain treatment and rehabilitation strategies. Neuroinflammation contributes to the transition from acute to chronic pain beyond tissue healing. Glial activation and mediators, such as TNF-α and IL-1β, drive central sensitization, while caspase cascades (caspase-1, -3, -6) regulate AMPA and NMDA receptor trafficking in the spinal cord, maintaining hypersensitivity. Clinical findings, including MRI studies of whiplash patients, demonstrate nerve root inflammation associated with hyperalgesia. Emerging therapies, such as transcutaneous vagus nerve stimulation (tVNS) and exosome-based approaches, show promise in modulating these processes. Neuroinflammation links musculoskeletal injury to persistent pain by combining immune activation and neural changes that sustain central sensitization. Understanding these mechanisms may help identify patients at risk and guide the development of treatments targeting neuroinflammation to prevent chronic pain.
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessNEUROINFLAMMATION AFTER MUSCULOSKELETAL TRAUMA - MISSING LINK BETWEEN ORTHOPEDIC INJURY AND CHRONIC PAIN?
Musculoskeletal injuries, such as fractures and whiplash, affect around 9 million people annually and are a major cause of disability. In many cases, pain persists despite tissue healing, which is not fully explained by traditional models. Increasing evidence suggests that neuroinflammation - the activation of the innate immune system in the peripheral and central nervous systems - may underlie chronic pain. It involves glial cell activation and the release of proinflammatory mediators, leading to central sensitization and maladaptive synaptic plasticity. To evaluate neuroinflammation as a potential “missing link” between orthopedic injury and chronic pain, and to identify therapeutic targets. A search of PubMed, Web of Science and Google Scholar was conducted. Included were randomized controlled trials, systematic review and meta-analyses of ankle sprain treatment and rehabilitation strategies. Neuroinflammation contributes to the transition from acute to chronic pain beyond tissue healing. Glial activation and mediators, such as TNF-α and IL-1β, drive central sensitization, while caspase cascades (caspase-1, -3, -6) regulate AMPA and NMDA receptor trafficking in the spinal cord, maintaining hypersensitivity. Clinical findings, including MRI studies of whiplash patients, demonstrate nerve root inflammation associated with hyperalgesia. Emerging therapies, such as transcutaneous vagus nerve stimulation (tVNS) and exosome-based approaches, show promise in modulating these processes. Neuroinflammation links musculoskeletal injury to persistent pain by combining immune activation and neural changes that sustain central sensitization. Understanding these mechanisms may help identify patients at risk and guide the development of treatments targeting neuroinflammation to prevent chronic pain.
- Open Access
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
MID-REGIONAL PRO-ADRENOMEDULLIN (MR-proADM) AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN EARLY SEPSIS: A NARRATIVE REVIEW
Sepsis is a critical medical condition resulting from an inappropriate host response to infection, often leading to organ dysfunction and high mortality. Early diagnosis remains a significant clinical challenge due to the nonspecific nature of initial symptoms and the limited efficacy of conventional biomarkers. Commonly used markers, such as C-reactive protein (CRP) and procalcitonin (PCT), provide useful information on inflammation and bacterial infections but do not adequately reflect vascular dysfunction or predict clinical deterioration. Mid-regional proadrenomedullin (MR-proADM) has recently gained importance as a biomarker reflecting both inflammatory processes and impaired vascular integrity. As a stable fragment of proadrenomedullin, it indirectly represents the activity of adrenomedullin, a peptide involved in maintaining endothelial function and circulatory homeostasis. Evidence from observational studies indicates that MR-proADM levels increase early in the course of infection and correlate with disease progression, organ failure, and risk of death. Compared to traditional biomarkers, MR-proADM appears to offer better prognostic performance, particularly in identifying patients at risk of severe complications. Its association with endothelial damage and microcirculatory dysfunction makes it particularly relevant to the pathophysiology of sepsis. In summary, MR-proADM may be a valuable complement to existing diagnostic tools, aiding early risk stratification and clinical decision-making. Further studies are needed to standardize its use and confirm its role in routine practice.
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessMID-REGIONAL PRO-ADRENOMEDULLIN (MR-proADM) AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN EARLY SEPSIS: A NARRATIVE REVIEW
Sepsis is a critical medical condition resulting from an inappropriate host response to infection, often leading to organ dysfunction and high mortality. Early diagnosis remains a significant clinical challenge due to the nonspecific nature of initial symptoms and the limited efficacy of conventional biomarkers. Commonly used markers, such as C-reactive protein (CRP) and procalcitonin (PCT), provide useful information on inflammation and bacterial infections but do not adequately reflect vascular dysfunction or predict clinical deterioration. Mid-regional proadrenomedullin (MR-proADM) has recently gained importance as a biomarker reflecting both inflammatory processes and impaired vascular integrity. As a stable fragment of proadrenomedullin, it indirectly represents the activity of adrenomedullin, a peptide involved in maintaining endothelial function and circulatory homeostasis. Evidence from observational studies indicates that MR-proADM levels increase early in the course of infection and correlate with disease progression, organ failure, and risk of death. Compared to traditional biomarkers, MR-proADM appears to offer better prognostic performance, particularly in identifying patients at risk of severe complications. Its association with endothelial damage and microcirculatory dysfunction makes it particularly relevant to the pathophysiology of sepsis. In summary, MR-proADM may be a valuable complement to existing diagnostic tools, aiding early risk stratification and clinical decision-making. Further studies are needed to standardize its use and confirm its role in routine practice.
- Open Access
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
THE ROLE OF THE MICROBIOME IN HASHIMOTO’S DISEASE - PATHOGENESIS AND THERAPEUTIC IMPLICATIONS: NARRATIVE REVIEW
Objective: The aim of this narrative review was to summarize the current state of knowledge regarding the role of the gut microbiome in the pathogenesis of Hashimoto’s disease and to discuss potential microbiome-targeted therapeutic strategies. Methods: A narrative literature review was conducted using publications indexed in the PubMed, Google Scholar and Scopus databases. Original research articles, systematic reviews, and meta-analyses focusing on Hashimoto’s disease and gut microbiota interactions were included. Most studies were selected from the past 10-15 years, with approximately 80% of the included literature published within the last five years (2021–2025), ensuring up-to-date evidence. Key findings: Available evidence indicates that patients with Hashimoto’s disease exhibit gut dysbiosis characterized by reduced microbial diversity, decreased abundance of short-chain fatty acid-producing bacteria, and an overrepresentation of potentially pathogenic microorganisms. These alterations are associated with impaired intestinal barrier integrity, increased systemic inflammation, and dysregulation of immune responses, particularly an imbalance between regulatory T cells and Th17 lymphocytes. Furthermore, microbiome disturbances may contribute to thyroid autoimmunity through mechanisms such as molecular mimicry and translocation of bacterial antigens. Emerging studies suggest that dietary modification, probiotic and synbiotic supplementation, and fecal microbiota transplantation may positively influence thyroid function and immune regulation. Conclusions: Although levothyroxine replacement remains the standard treatment for Hashimoto’s disease, modulation of the gut microbiome represents a promising adjunctive therapeutic approach. Further well-designed clinical trials are required to clarify causal relationships and evaluate the efficacy of microbiome-targeted interventions in autoimmune thyroid disease.
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessTHE ROLE OF THE MICROBIOME IN HASHIMOTO’S DISEASE - PATHOGENESIS AND THERAPEUTIC IMPLICATIONS: NARRATIVE REVIEW
Objective: The aim of this narrative review was to summarize the current state of knowledge regarding the role of the gut microbiome in the pathogenesis of Hashimoto’s disease and to discuss potential microbiome-targeted therapeutic strategies. Methods: A narrative literature review was conducted using publications indexed in the PubMed, Google Scholar and Scopus databases. Original research articles, systematic reviews, and meta-analyses focusing on Hashimoto’s disease and gut microbiota interactions were included. Most studies were selected from the past 10-15 years, with approximately 80% of the included literature published within the last five years (2021–2025), ensuring up-to-date evidence. Key findings: Available evidence indicates that patients with Hashimoto’s disease exhibit gut dysbiosis characterized by reduced microbial diversity, decreased abundance of short-chain fatty acid-producing bacteria, and an overrepresentation of potentially pathogenic microorganisms. These alterations are associated with impaired intestinal barrier integrity, increased systemic inflammation, and dysregulation of immune responses, particularly an imbalance between regulatory T cells and Th17 lymphocytes. Furthermore, microbiome disturbances may contribute to thyroid autoimmunity through mechanisms such as molecular mimicry and translocation of bacterial antigens. Emerging studies suggest that dietary modification, probiotic and synbiotic supplementation, and fecal microbiota transplantation may positively influence thyroid function and immune regulation. Conclusions: Although levothyroxine replacement remains the standard treatment for Hashimoto’s disease, modulation of the gut microbiome represents a promising adjunctive therapeutic approach. Further well-designed clinical trials are required to clarify causal relationships and evaluate the efficacy of microbiome-targeted interventions in autoimmune thyroid disease.
- Open Access
- 16 April 2026
- Published by John Paul II University in Biała Podlaska in Health Problems of Civilization
Microplastics – why are they everywhere within the body and where do they come from? A review
Microplastics (MPs) have been detected in nearly all environmental compartments. The crucial routes of human exposure include the indoor environment, where the concentration of airborne fibers is higher than outdoors, the consumption of contaminated food, and contact with cookware, medical equipment, and personal care products made from or containing plastic. Depending on how MPs enter the body, through ingestion, inhalation, or dermal contact, they can reach a variety of organs. In this study, we focus on the detection of MPs and their consequences in several organs, which have not been sufficiently described in literature before, including the kidneys, placenta, testes, heart, brain, bone marrow, and in bodily secretions, namely semen and breast milk. To ensure the most accurate and up-to-date data, the presented results are based on papers published within the past three years. Experimental and clinical studies link exposure to MPs to oxidative stress, inflammation, dysbiosis, mitochondrial damage, fibrosis, and potential carcinogenic and neurotoxic effects. These mechanisms, occurring in the aforementioned tissues, raise concerns regarding fertility, fetal development, metabolic health, and neurodegeneration. However, further improvements in detection of MPs and contamination prevention methods are needed to minimize the potential health risks associated with exposure.
- 16 April 2026
- Published by John Paul II University in Biała Podlaska in Health Problems of Civilization
Open AccessMicroplastics – why are they everywhere within the body and where do they come from? A review
Microplastics (MPs) have been detected in nearly all environmental compartments. The crucial routes of human exposure include the indoor environment, where the concentration of airborne fibers is higher than outdoors, the consumption of contaminated food, and contact with cookware, medical equipment, and personal care products made from or containing plastic. Depending on how MPs enter the body, through ingestion, inhalation, or dermal contact, they can reach a variety of organs. In this study, we focus on the detection of MPs and their consequences in several organs, which have not been sufficiently described in literature before, including the kidneys, placenta, testes, heart, brain, bone marrow, and in bodily secretions, namely semen and breast milk. To ensure the most accurate and up-to-date data, the presented results are based on papers published within the past three years. Experimental and clinical studies link exposure to MPs to oxidative stress, inflammation, dysbiosis, mitochondrial damage, fibrosis, and potential carcinogenic and neurotoxic effects. These mechanisms, occurring in the aforementioned tissues, raise concerns regarding fertility, fetal development, metabolic health, and neurodegeneration. However, further improvements in detection of MPs and contamination prevention methods are needed to minimize the potential health risks associated with exposure.
- Open Access
- 25 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
ALGORITHMIC AUTHORITY VS. HUMAN TOUCH: A NARRATIVE REVIEW OF PATIENT TRUST AND CLINICAL AUTONOMY IN AI-ASSISTED DIAGNOSTICS
Introduction: Contemporary medicine is undergoing an unprecedented transformation driven by the integration of advanced artificial intelligence (AI) and large language models (LLMs) into clinical workflows. While these technologies objectively enhance diagnostic precision, their implementation creates a fundamental paradox: the increase in technological efficacy often correlates with a decline in patient trust, known as the "AI trust gap." This review examines the tension between algorithmic authority and the necessity of the "human touch," analyzing the impact of digital innovations on clinical autonomy and the patient-physician-AI triad. Materials and Methods: This study presents a detailed analysis of 44 peer-reviewed scientific articles published between 2022 and 2026. The review focuses on Clinical Decision Support Systems (CDSS) across key diagnostic areas, including radiology and pathology. The analysis encompasses the psychological mechanisms of AI acceptance, the risks of automation bias, and the potential of Explainable AI (XAI) to restore clinical transparency. Key Findings: Research reveals that the mere disclosure of AI involvement can reduce patient trust (dropping from 0.50 to 0.30–0.34 in experimental settings). A "paradox of knowledge" was identified, where higher patient literacy regarding AI correlates with increased skepticism. Regarding clinical autonomy, a dichotomy exists: junior clinicians are prone to automation bias, while experts face the risk of "deskilling." The review also discusses the "Algorithmic Consultant" role and the necessity of "Triadic Decision-Making," where AI serves as a transparent partner rather than a black-box authority. Conclusions: The integration of AI requires a reconfiguration of medical practice from a technology-first approach to a human-centered design. Preserving clinical autonomy depends on adopting a "trust but verify" model and implementing XAI strategies to mitigate transparency barriers. The success of algorithmic medicine relies on maintaining the physician's judgment as the cornerstone of care, ensuring that AI functions as a supportive co-pilot.
- 25 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
Open AccessALGORITHMIC AUTHORITY VS. HUMAN TOUCH: A NARRATIVE REVIEW OF PATIENT TRUST AND CLINICAL AUTONOMY IN AI-ASSISTED DIAGNOSTICS
Introduction: Contemporary medicine is undergoing an unprecedented transformation driven by the integration of advanced artificial intelligence (AI) and large language models (LLMs) into clinical workflows. While these technologies objectively enhance diagnostic precision, their implementation creates a fundamental paradox: the increase in technological efficacy often correlates with a decline in patient trust, known as the "AI trust gap." This review examines the tension between algorithmic authority and the necessity of the "human touch," analyzing the impact of digital innovations on clinical autonomy and the patient-physician-AI triad. Materials and Methods: This study presents a detailed analysis of 44 peer-reviewed scientific articles published between 2022 and 2026. The review focuses on Clinical Decision Support Systems (CDSS) across key diagnostic areas, including radiology and pathology. The analysis encompasses the psychological mechanisms of AI acceptance, the risks of automation bias, and the potential of Explainable AI (XAI) to restore clinical transparency. Key Findings: Research reveals that the mere disclosure of AI involvement can reduce patient trust (dropping from 0.50 to 0.30–0.34 in experimental settings). A "paradox of knowledge" was identified, where higher patient literacy regarding AI correlates with increased skepticism. Regarding clinical autonomy, a dichotomy exists: junior clinicians are prone to automation bias, while experts face the risk of "deskilling." The review also discusses the "Algorithmic Consultant" role and the necessity of "Triadic Decision-Making," where AI serves as a transparent partner rather than a black-box authority. Conclusions: The integration of AI requires a reconfiguration of medical practice from a technology-first approach to a human-centered design. Preserving clinical autonomy depends on adopting a "trust but verify" model and implementing XAI strategies to mitigate transparency barriers. The success of algorithmic medicine relies on maintaining the physician's judgment as the cornerstone of care, ensuring that AI functions as a supportive co-pilot.